Legend Biotech (LEGN) Stock Price, Financials & Analysis

Key Stats

Market Cap3.88 Bn

P/E–

FCF (Yr)–

ROA (Yr)–

EV to EBIT–

Net Income (Yr)–

Enterprise Value722.37 Mn

Add ratio to table…

About

Legend Biotech Corporation is a global biopharmaceutical company focused on the discovery development manufacturing and commercialization of novel cell therapies for oncology and other indications. The company leverages its proprietary technology and integrated capabilities to advance product candidates from research through clinical testing to market. Legend Biotech Corporation generates revenue primarily from the sale of its approved CAR T therapy CARVYKTI which treats…

How Legend Biotech ranks

Ranked against the 671 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 6, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last

P/ENegative earnings −45.3xMedian 17.8x 83^rd
P/FCFNegative free cash flow −64.3xMedian 21.0x 82^nd
P/Operating cash flowNegative operating cash flow −46.5xMedian 16.8x 80^th
P/S 3.27xMedian 8.14x 68^th
P/B 3.38xMedian 2.02x 34^th
P/Tangible book 3.38xMedian 2.24x 37^th
EV/EBITDA 917xMedian 15.7x 79^th
EV/EBITNegative EBIT −65.8xMedian 20.9x 80^th
EV/Revenue 2.86xMedian 5.92x 67^th
EV/FCFNegative free cash flow −56.3xMedian 22.0x 78^th
EV/Operating cash flowNegative operating cash flow −40.7xMedian 18.3x 76^th
PEG (3Y EPS CAGR)Negative earnings −0.96Median 0.36 Not meaningful —

Growth

14 metrics · Year-on-year growth and three-year compound annual growth

Revenue growth (1Y) 59.5%Median 11.0% 74^th
Revenue CAGR (3Y) 97.6%Median 10.4% 86^th
Gross profit growth (1Y) 42.4%Median 11.8% 74^th
Gross profit CAGR (3Y) 148%Median 12.3% 94^th
Operating income growth (1Y) 75.3%Median −1.6% 92^nd
Operating income CAGR (3Y) 49.1%Median 1.4% 92^nd
Net income growth (1Y) 75.3%Median −3.3% 90^th
Net income CAGR (3Y) 46.7%Median −0.1% 91^st
EPS growth (1Y) 72.0%Median 22.4% 79^th
EPS CAGR (3Y) 47.0%Median 25.9% 73^rd
Operating cash flow growth (1Y) 67.5%Median −0.4% 90^th
Operating cash flow CAGR (3Y) 37.1%Median 2.1% 88^th
Free cash flow growth (1Y) 77.8%Median −0.1% 91^st
Free cash flow CAGR (3Y) 44.5%Median 2.5% 91^st

Profitability

14 metrics · Margins, returns on capital and the quality of earnings

Gross margin 57.2%Median 74.2% 30^th
EBITDA margin 0.3%Median −214% 75^th
Operating margin −4.3%Median −213% 75^th
Pretax margin −4.4%Median −205% 76^th
Net margin −7.2%Median −196% 74^th
FCF margin −5.1%Median −181% 73^rd
Operating cash flow margin −7.0%Median −175% 72^nd
Return on equity −8.3%Median −54.7% 81^st
Return on assets −5.5%Median −41.1% 82^nd
Return on invested capital −4.2%Median −5.3% 51^st
Return on capital employed −4.3%Median −47.8% 83^rd
Asset turnover 0.76xMedian 0.18x 86^th
Cash conversion (OCF / net income)Net income is not positive 1.11xMedian 1.14x Not meaningful —
Stock comp / revenue 5.2%Median 29.2% 81^st

Financial Health

11 metrics · Leverage, liquidity and solvency; less debt ranks higher

Debt / assets 8.9%Median 20.0% 67^th
Debt / equity 0.13xMedian 0.27x 64^th
Net debt / EBITDA −130xMedian 1.22x 99^th
Debt / FCFFree cash flow is not positive −2.42xMedian 3.65x Not meaningful —
Liabilities / assets 29.8%Median 32.3% 53^rd
Equity / assets 70.2%Median 67.7% 53^rd
Interest coverage −4.83xMedian −10.0x 61^st
Current ratio 3.04xMedian 4.37x 38^th
Quick ratio 1.67xMedian 3.65x 30^th
Cash ratio 1.67xMedian 3.35x 35^th
Altman Z-score 6.95Median −0.80 80^th

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,264.65 Bn	45.85	14.63	49.50 Bn
2	JNJ	Johnson & Johnson	677.74 Bn	42.11	6.82	44.65 Bn
3	ABBV	AbbVie Inc.	517.10 Bn	50.00	7.83	80.90 Bn
4	MRK	Merck & Co., Inc.	362.23 Bn	147.67	5.38	53.78 Bn
5	NVS	Novartis Ag	315.90 Bn	24.55	6.03	9.59 Bn
6	AZN	Astrazeneca Plc	289.40 Bn	33.26	5.34	32.35 Bn
7	AMGN	Amgen Inc	249.90 Bn	26.61	6.42	54.01 Bn
8	LEGN	Legend Biotech Corp	3.88 Bn	-	-	0.32 Bn

Legend Biotech LEGN

About

Timing of transfer of goods or services [axis] Breakdown of Revenue (2024)

How Legend Biotech ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Legend Biotech LEGN

About

Timing of transfer of goods or services [axis] Breakdown of Revenue (2024)

How Legend Biotech ranks

Valuation

Growth

Profitability

Financial Health

Shareholder Returns

Peer Comparison

Create an account

Sign In

Reset Password